Study shows Seladelpar improves liver bio markers for PBC patients

Study shows Seladelpar improves liver bio markers for PBC patients

In an oral presentation at the AASLD Liver Meeting November 2021, titled “Long-Term Safety and Efficacy of Seladelpar in Patients with Primary Biliary Cholangitis”1 Marlyn J. Mayo, MD, Professor and Liver Disease Specialist, University of Texas Southwestern Medical Center presented data from an open label, Long-Term Extension Study, highlighting the efficacy and safety of seladelpar at one and two years of treatment in patients with primary biliary cholangitis (PBC)  Read more